<DOC>
	<DOCNO>NCT00703937</DOCNO>
	<brief_summary>The objective study evaluate safety FCM patient anemia dialysis dependent .</brief_summary>
	<brief_title>Safety Tolerability Ferric Carboxymaltose ( FCM ) Versus Standard Care Treating Iron Deficiency Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Subjects ≥ 18 year age able give inform consent Iron deficiency primary etiology anemia Screening Visit central laboratory Hemoglobin ( Hgb ) ≤ 11g/dL Screening Visit ferritin ≤ 100ng/mL ≤ 300 ng/mL TSAT ≤ 30 % Previous participation FCM trial Known hypersensitivity reaction FCM Requires dialysis treatment chronic kidney disease Current anemia attribute iron deficiency Received IV iron , RBC transfusion ( ) , antibiotic 10 day prior screen phase Anticipated need surgery AST ALT great 1.5 time upper limit normal Received investigational drug within 30 day screen Pregnant sexuallyactive female willing use effective form birth control</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>